These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 15314880)

  • 1. Current concepts in antiplatelet therapy for cardiovascular disease.
    Martinez A
    JAAPA; 2004 Mar; 17(3):16-20, 23-4; quiz 51-2. PubMed ID: 15314880
    [No Abstract]   [Full Text] [Related]  

  • 2. Antiplatelet medications: old and emerging therapies.
    Stone WM; Naidu SG; Chapital A; Money SR
    Ann Vasc Surg; 2010 Jan; 24(1):140-8. PubMed ID: 19619976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of antiplatelet agents in cardiac disease.
    Tepper D; Ip RJ; Ip JH
    Manag Care Interface; 2000 May; 13(5):76-8. PubMed ID: 11067401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiplatelet agents: current drugs and future trends.
    Messmore HL; Jeske WP; Wehrmacher W; Coyne E; Mobarhan S; Cho L; Leya FS; Moran JF
    Hematol Oncol Clin North Am; 2005 Feb; 19(1):87-117, vi. PubMed ID: 15639110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring oral antiplatelet therapy: is it justified?
    Ang L; Mahmud E
    Ther Adv Cardiovasc Dis; 2008 Dec; 2(6):485-96. PubMed ID: 19124443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should we monitor platelet function during antiplatelet therapy?
    Hjemdahl P
    Heart; 2008 Jun; 94(6):685-7. PubMed ID: 18480343
    [No Abstract]   [Full Text] [Related]  

  • 7. New players in the field of antiplatelet and anticoagulant therapy in coronary heart disease - current therapeutic issues and hot topics.
    Schindler C
    Ther Adv Cardiovasc Dis; 2009 Dec; 3(6):413-21. PubMed ID: 19917636
    [No Abstract]   [Full Text] [Related]  

  • 8. Platelet biology and response to antiplatelet therapy in women: implications for the development and use of antiplatelet pharmacotherapies for cardiovascular disease.
    Wang TY; Angiolillo DJ; Cushman M; Sabatine MS; Bray PF; Smyth SS; Dauerman HL; French PA; Becker RC
    J Am Coll Cardiol; 2012 Mar; 59(10):891-900. PubMed ID: 22381424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The brave new world of antiplatelet therapy: seeking clarity in a world of increasing choice and complexity.
    Price MJ
    Rev Cardiovasc Med; 2011; 12 Suppl 1():S1-3. PubMed ID: 22080982
    [No Abstract]   [Full Text] [Related]  

  • 10. Current concepts about inhibition of platelet aggregation.
    de Gaetano G; Crescente M; Cerletti C
    Platelets; 2008 Dec; 19(8):565-70. PubMed ID: 19012174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiology patient page. Platelets and cardiovascular disease.
    Gregg D; Goldschmidt-Clermont PJ
    Circulation; 2003 Sep; 108(13):e88-90. PubMed ID: 14517153
    [No Abstract]   [Full Text] [Related]  

  • 12. Genetic and acquired determinants of individual variability of response to antiplatelet drugs.
    Schafer AI
    Circulation; 2003 Aug; 108(8):910-1. PubMed ID: 12939239
    [No Abstract]   [Full Text] [Related]  

  • 13. Hypersensitivity of platelets to adenosine diphosphate in patients with stable cardiovascular disease predicts major adverse events despite antiplatelet therapy.
    Christie DJ; Kottke-Marchant K; Gorman RT
    Platelets; 2008 Mar; 19(2):104-10. PubMed ID: 17852773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet inhibitor therapy for patients with cardiovascular disease: looking toward the future.
    Aljaroudi WA; Halabi AR; Harrington RA
    Curr Hematol Rep; 2005 Sep; 4(5):397-404. PubMed ID: 16131442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet perturbations in diabetes: implications for cardiovascular disease risk and treatment.
    Mathewkutty S; McGuire DK
    Expert Rev Cardiovasc Ther; 2009 May; 7(5):541-9. PubMed ID: 19419262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future.
    Raju NC; Eikelboom JW; Hirsh J
    Nat Clin Pract Cardiovasc Med; 2008 Dec; 5(12):766-80. PubMed ID: 18957959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controversies in antiplatelet therapy for patients with cardiovascular disease.
    Bates ER; Lau WC
    Circulation; 2005 May; 111(17):e267-71. PubMed ID: 15867186
    [No Abstract]   [Full Text] [Related]  

  • 18. Controversies surrounding platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention and acute coronary syndromes.
    Harrington RA
    Semin Thromb Hemost; 2004 Dec; 30(6):639-47. PubMed ID: 15630670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel antithrombotic strategies in cardiovascular diseases.
    Golino P; Loffredo F; Riegler L; Renzullo E; Cocchia R
    Curr Opin Investig Drugs; 2005 Mar; 6(3):298-306. PubMed ID: 15816507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence-based prescribing and adherence to antiplatelet therapy--how much difference do they make to patients with atherothrombosis?
    Husted S
    Int J Cardiol; 2009 May; 134(2):150-9. PubMed ID: 19282042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.